AusAm Biotechnologies Accumin Urine Albumin Test To Indicate Risk Of Complications From Heart And Kidney Disease To Be Available To Hospitals Nationwide Through Quest Diagnostics Inc.
10/19/2005 5:12:31 PM
NEW YORK--(BUSINESS WIRE)--Dec. 21, 2004--AusAm Biotechnologies, Inc. announced today that its Accumin(TM) test for detection of the protein albumin in urine will be offered by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services. The presence of relatively high levels of albumin in the urine, a condition known as microalbuminuria, is an indicator of elevated risk for developing cardiovascular disease complications and kidney disease. The test will be available to hospital-based physicians nationwide in the first quarter of 2005 through Quest Diagnostics. Terms of the transaction were not disclosed.
comments powered by